IP Transactions

●   Represented Hanx Biopharmaceuticals (Wuhan) Co., Ltd. in a series of license and collaboration transactions

     with various pharmaceutical and biotech companies.

●   Represented CARsgen Therapeutics in collaboration and license agreements with multiple biotech companies.

●   Represented Synceptor, Inc. in various IP agreements.

●   Represented Shanghai CirCode Biomed Co., Ltd. in a series of collaboration agreements with (1) multinational

     pharmaceutical companies including Pfizer, Johnson & Johnson, and BMS, (2) Chinese biotech companies, 

     and (3) universities.

●   Represented Betta Pharmaceuticals Co., Ltd. in collaboration and license agreements with multiple biotech and

     biopharma companies, as well as the related IP due diligence matters.

●   Represented Jiangsu Yahong Meditech Co., Ltd. in (1) an exclusive license agreement and supply agreement with

     a U.S. biotech company, and (2) an exclusive collaboration and license agreement with a Chinese biotech company.

●   Represented IntuitiveFosun in a collaboration and license agreement with a Chinese biotech company.

●   Represented LeaderMed Health Group Limited in (1) subscription of a convertible note and an exclusive license

     agreement with Aqualung Therapeutics Corporation to develop, manufacture, and commercialize Aqualung’s clinical

     stage antibody product ALT-100 in eight Asian territories, including Greater China, and (2) the formation of a joint

     venture and exclusive license agreement with OPKO Health, Inc. to develop, manufacture, and commercialize two

     of OPKO’s clinical stage, long-acting drug products, Oxyntomodulin and Factor VIIa-CTP, in Greater China and

     eight other Asian territories.

●   Represented Zhongze Therapeutics (Cayman) Holding, Ltd. in an exclusive license and collaboration agreement

     with Digestome Therapeutics, Inc. to develop, manufacture, and commercialize Digestome’s first-in-class oral

     therapeutic ALT-100 in the Greater China territory.

●   Represented Huadong Medicine Co. Ltd. in (1) an exclusive license and collaboration agreement with PulseCath

     B.V. to develop and commercialize iVAC technology in Greater China and selected other Asian Pacific countries,

     (2) the negotiation and signing of a research cooperation agreement with Exscientia, a world-leading, clinical-stage

     Artificial Intelligence (AI) drug discovery company, and (3) its subscription of Series B Preferred Shares of R2

     Dermatology, Inc., and the negotiation of a distribution agreement authorizing Huadong Medicine as an exclusive

     distributor in Asia for R2’s skin whitening products.

●   Represented Incyte Corporation in (1) its sublicense out to Zai Lab Limited of certain intellectual property rights to

     an anti-PD1 molecule licensed to Incyte from MacroGenics, Inc. globally in 2017 and which Incyte is actively

     developing in the U.S. and other jurisdictions outside of China, and (2) its strategic collaboration and license out

     agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical

     stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment

     of hematological and oncological diseases.

●   Represented Sequoia China in connection with its purchase of Series B Convertible Preferred Stock in a private

     placement by HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell

     screening and analysis.

IP Litigation

●   Advised a U.S. pharmaceutical company in patent linkage cases against a Chinese generic company.
●   Advised a U.S. pharmaceutical company in patent linkage cases and patent invalidation actions against a Chinese

     generic company.
●   Advise a global top 10 pharmaceutical company in patent invalidation actions in China.
●   Represented a major pharmaceutical company in a Hong Kong International Arbitration Centre arbitration arising

     out of representations and warranties given in respect of the client’s investment in a Chinese drug development

     company whose senior officers and consultants were subsequently prosecuted in the United States for

     misappropriation of another pharmaceutical company’s trade secrets.
●   Advised Cree, Inc. and its Chinese subsidiary in fending off six patent infringement cases against a non-practicing

     entity in China.
●   Represented a Chinese biotech company in a trade secret misappropriation criminal case against the U.S.

     government.
●   Represented a Chinese pharmaceutical company in a trade secret misappropriation and wire fraud criminal case

     against the U.S. government.
●   Represented SharkNinja Operating LLC against Flexible Technologies, Inc.’s claims of patent infringement,

     misappropriation of trade secrets, and breach of a confidentiality agreement relating to the development of an

     electrified stretch e-hose for SharkNinja vacuum cleaners.
●   Represent Idenix (Merck & Co.) in enforcing Idenix’ U.S. Patent No. 7,608,597 against Gilead, obtaining the largest

     patent infringement verdict against Gilead for its hepatitis C drugs Sovaldi® and Harvoni®.
●   Represented Hyundai Motor America in a patent infringement suit filed in the District of Minnesota related to vehicle

     telematics. 

Awards

●   Rising Star—China, 2018, IP Stars from Managing IP 
●   Next Generation Partner, 2022, The Legal 500

●   Next Generation Partner, 2023, The Legal 500

Publications

●   September 2022: 
Women in IP Speaker Series: Global Patent Considerations: Written Description and Enablement
●   September 2021: 
Patent Linkage and Article 76 Proceedings in China: A Litigator’s Perspective
●   February 2021: 
Protecting AI Innovations Through Trade Secrets and Patent Protection
●   November 2020: 
China Promulgates Fourth Amendment to Patent Law
●   Spring 2011: 
Strategies for Trade Secrets Protection in China